Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More
Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More
DIVIS LABORATORIES | GLENMARK PHARMA | DIVIS LABORATORIES/ GLENMARK PHARMA |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 59.7 | 15.6 | 383.3% | View Chart |
P/BV | x | 13.8 | 2.6 | 537.8% | View Chart |
Dividend Yield | % | 0.4 | 0.4 | 112.9% |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
DIVIS LABORATORIES Mar-19 |
GLENMARK PHARMA Mar-19 |
DIVIS LABORATORIES/ GLENMARK PHARMA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 1,639 | 712 | 230.4% | |
Low | Rs | 1,115 | 484 | 230.6% | |
Sales per share (Unadj.) | Rs | 186.3 | 349.6 | 53.3% | |
Earnings per share (Unadj.) | Rs | 51.0 | 32.8 | 155.4% | |
Cash flow per share (Unadj.) | Rs | 57.3 | 44.3 | 129.3% | |
Dividends per share (Unadj.) | Rs | 16.00 | 2.00 | 800.0% | |
Dividend yield (eoy) | % | 1.2 | 0.3 | 347.2% | |
Book value per share (Unadj.) | Rs | 261.8 | 198.6 | 131.8% | |
Shares outstanding (eoy) | m | 265.47 | 282.17 | 94.1% | |
Bonus/Rights/Conversions | - | - | - | ||
Price / Sales ratio | x | 7.4 | 1.7 | 432.4% | |
Avg P/E ratio | x | 27.0 | 18.2 | 148.3% | |
P/CF ratio (eoy) | x | 24.0 | 13.5 | 178.2% | |
Price / Book Value ratio | x | 5.3 | 3.0 | 174.9% | |
Dividend payout | % | 31.4 | 6.1 | 514.7% | |
Avg Mkt Cap | Rs m | 365,592 | 168,625 | 216.8% | |
No. of employees | `000 | 11.8 | 12.0 | 98.4% | |
Total wages/salary | Rs m | 5,423 | 20,561 | 26.4% | |
Avg. sales/employee | Rs Th | 4,175.1 | 8,196.0 | 50.9% | |
Avg. wages/employee | Rs Th | 457.7 | 1,708.1 | 26.8% | |
Avg. net profit/employee | Rs Th | 1,141.8 | 768.5 | 148.6% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 49,463 | 98,655 | 50.1% | |
Other income | Rs m | 1,556 | 2,081 | 74.8% | |
Total revenues | Rs m | 51,019 | 100,736 | 50.6% | |
Gross profit | Rs m | 18,718 | 15,858 | 118.0% | |
Depreciation | Rs m | 1,689 | 3,259 | 51.8% | |
Interest | Rs m | 35 | 3,346 | 1.0% | |
Profit before tax | Rs m | 18,551 | 11,335 | 163.7% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 1,672 | 0.0% | |
Tax | Rs m | 5,023 | 3,756 | 133.7% | |
Profit after tax | Rs m | 13,527 | 9,250 | 146.2% | |
Gross profit margin | % | 37.8 | 16.1 | 235.4% | |
Effective tax rate | % | 27.1 | 33.1 | 81.7% | |
Net profit margin | % | 27.3 | 9.4 | 291.7% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 46,501 | 66,968 | 69.4% | |
Current liabilities | Rs m | 8,468 | 40,211 | 21.1% | |
Net working cap to sales | % | 76.9 | 27.1 | 283.5% | |
Current ratio | x | 5.5 | 1.7 | 329.7% | |
Inventory Days | Days | 131 | 83 | 157.0% | |
Debtors Days | Days | 86 | 81 | 105.7% | |
Net fixed assets | Rs m | 25,797 | 33,322 | 77.4% | |
Share capital | Rs m | 531 | 282 | 188.1% | |
"Free" reserves | Rs m | 68,962 | 55,770 | 123.7% | |
Net worth | Rs m | 69,493 | 56,052 | 124.0% | |
Long term debt | Rs m | 0 | 35,738 | 0.0% | |
Total assets | Rs m | 80,383 | 132,888 | 60.5% | |
Interest coverage | x | 531.0 | 4.4 | 12,102.8% | |
Debt to equity ratio | x | 0 | 0.6 | 0.0% | |
Sales to assets ratio | x | 0.6 | 0.7 | 82.9% | |
Return on assets | % | 16.9 | 9.5 | 178.0% | |
Return on equity | % | 19.5 | 16.5 | 118.0% | |
Return on capital | % | 26.7 | 17.8 | 150.1% | |
Exports to sales | % | 0 | 0 | - | |
Imports to sales | % | 24.6 | 0 | - | |
Exports (fob) | Rs m | NA | NA | - | |
Imports (cif) | Rs m | 12,187 | NA | - | |
Fx inflow | Rs m | 41,238 | 62,998 | 65.5% | |
Fx outflow | Rs m | 12,405 | 22,859 | 54.3% | |
Net fx | Rs m | 28,833 | 40,140 | 71.8% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 9,543 | 13,242 | 72.1% | |
From Investments | Rs m | -6,854 | -6,990 | 98.1% | |
From Financial Activity | Rs m | -2,459 | -7,387 | 33.3% | |
Net Cashflow | Rs m | 230 | -2,971 | -7.7% |
Indian Promoters | % | 52.0 | 48.3 | 107.7% | |
Foreign collaborators | % | 0.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 11.8 | 6.9 | 171.0% | |
FIIs | % | 19.0 | 34.4 | 55.2% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 17.2 | 10.5 | 163.8% | |
Shareholders | 31,796 | 56,727 | 56.1% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare DIVIS LABORATORIES With: STERLING BIOTECH SANOFI INDIA ALKEM LABORATORIES ORCHID PHARMA PFIZER
Compare DIVIS LABORATORIES With: MYLAN (US) ACTAVIS (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
Share markets in India are presently trading marginally higher. The BSE Sensex is trading up by 140 points, up 0.3% at 49,538 levels.
For the quarter ended June 2020, GLENMARK PHARMA has posted a net profit of Rs 3 bn (up 132.5% YoY). Sales on the other hand came in at Rs 23 bn (up 0.9% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.
For the quarter ended June 2020, DIVIS LABORATORIES has posted a net profit of Rs 5 bn (up 84.1% YoY). Sales on the other hand came in at Rs 17 bn (up 50.0% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.
For the quarter ended March 2020, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 35.4% YoY). Sales on the other hand came in at Rs 14 bn (up 9.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.
For the quarter ended December 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 64.0% YoY). Sales on the other hand came in at Rs 27 bn (up 7.1% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.
For the quarter ended December 2019, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (down 4.9% YoY). Sales on the other hand came in at Rs 14 bn (up 3.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.
More Views on NewsThe smallcap rally has enough steam left in it. If you haven't joined yet, it is still not too late.
The charts are telling the bulls to be cautious.
Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...
Our ace stock picker is ready to capitalise on a big growth opportunity.
More